71 related articles for article (PubMed ID: 9495805)
41. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
[TBL] [Abstract][Full Text] [Related]
42. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.
VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
Drug Metab Dispos; 2012 Jan; 40(1):47-53. PubMed ID: 21976621
[TBL] [Abstract][Full Text] [Related]
43. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
44. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
[TBL] [Abstract][Full Text] [Related]
45. Mitochondrial porin can be translocated across both endoplasmic reticulum and mitochondrial membranes.
Sakaguchi M; Hachiya N; Mihara K; Omura T
J Biochem; 1992 Aug; 112(2):243-8. PubMed ID: 1328170
[TBL] [Abstract][Full Text] [Related]
46. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
[TBL] [Abstract][Full Text] [Related]
47. Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6.
Narimatsu S; Kato R; Horie T; Ono S; Tsutsui M; Yabusaki Y; Ohmori S; Kitada M; Ichioka T; Shimada N; Kato R; Ishikawa T
Chirality; 1999; 11(1):1-9. PubMed ID: 9914647
[TBL] [Abstract][Full Text] [Related]
48. Topological role of cytochrome P450 2D6 active site residues.
van Waterschoot RA; Keizers PH; de Graaf C; Vermeulen NP; Tschirret-Guth RA
Arch Biochem Biophys; 2006 Mar; 447(1):53-8. PubMed ID: 16466686
[TBL] [Abstract][Full Text] [Related]
49. Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro.
Wang Z; Wang L; Xu RA; Zhan YY; Huang CK; Dai DP; Cai JP; Hu GX
Drug Des Devel Ther; 2016; 10():1909-16. PubMed ID: 27354764
[TBL] [Abstract][Full Text] [Related]
50. Topogenesis of a microsomal cytochrome P450 and induction of endoplasmic reticulum membrane proliferation in Saccharomyces cerevisiae.
Menzel R; Kärgel E; Vogel F; Böttcher C; Schunck WH
Arch Biochem Biophys; 1996 Jun; 330(1):97-109. PubMed ID: 8651709
[TBL] [Abstract][Full Text] [Related]
51. Vesicular transport of newly synthesized cytochromes P4501A to the outside of rat hepatocyte plasma membranes.
Robin MA; Descatoire V; Le Roy M; Berson A; Lebreton FP; Maratrat M; Ballet F; Loeper J; Pessayre D
J Pharmacol Exp Ther; 2000 Sep; 294(3):1063-9. PubMed ID: 10945860
[TBL] [Abstract][Full Text] [Related]
52. Tryptamine: a possible endogenous substrate for CYP2D6.
Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J
Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145
[TBL] [Abstract][Full Text] [Related]
53. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan.
Uehara S; Uno Y; Hagihira Y; Murayama N; Shimizu M; Inoue T; Sasaki E; Yamazaki H
Xenobiotica; 2015; 45(9):766-72. PubMed ID: 25801057
[TBL] [Abstract][Full Text] [Related]
54. Transgenic HepaRG cells expressing CYP2D6 as an improved model of primary human hepatocytes.
Okuyama S; Mine A; Nakamura T; Ohasi Y; Seto M; Tada M
Pharmacol Res Perspect; 2022 Apr; 10(2):e00939. PubMed ID: 35174659
[TBL] [Abstract][Full Text] [Related]
55. Cytochrome P450 associated with insecticide resistance catalyzes cuticular hydrocarbon production in Anopheles gambiae.
Balabanidou V; Kampouraki A; MacLean M; Blomquist GJ; Tittiger C; Juárez MP; Mijailovsky SJ; Chalepakis G; Anthousi A; Lynd A; Antoine S; Hemingway J; Ranson H; Lycett GJ; Vontas J
Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9268-73. PubMed ID: 27439866
[TBL] [Abstract][Full Text] [Related]
56. Proteasome inhibition compromises direct retention of cytochrome P450 2C2 in the endoplasmic reticulum.
Szczesna-Skorupa E; Kemper B
Exp Cell Res; 2008 Oct; 314(17):3221-31. PubMed ID: 18755184
[TBL] [Abstract][Full Text] [Related]
57. Pheromone anosmia in a scarab beetle induced by in vivo inhibition of a pheromone-degrading enzyme.
Maïbèche-Coisne M; Nikonov AA; Ishida Y; Jacquin-Joly E; Leal WS
Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11459-64. PubMed ID: 15277687
[TBL] [Abstract][Full Text] [Related]
58. Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.
Boitier E; Beaune P
Clin Rev Allergy Immunol; 2000 Apr; 18(2):215-39. PubMed ID: 10944706
[No Abstract] [Full Text] [Related]
59. Topology inversion of CYP2D6 in the endoplasmic reticulum is not required for plasma membrane transport.
Loeper J; Le Berre A; Pompon D
Mol Pharmacol; 1998 Mar; 53(3):408-14. PubMed ID: 9495805
[TBL] [Abstract][Full Text] [Related]
60. Yeast expressed cytochrome P450 2D6 (CYP2D6) exposed on the external face of plasma membrane is functionally competent.
Loeper J; Louérat-Oriou B; Duport C; Pompon D
Mol Pharmacol; 1998 Jul; 54(1):8-13. PubMed ID: 9658184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
